Results 21 to 30 of about 1,549,234 (325)
Pharmacology Research & Perspectives, 2022 The American Society for Pharmacology and Experimental Therapeutics (ASPET) held its annual meeting at the Experimental Biology 2022 conference in Philadelphia, PA on April 2–5, 2022.
Joe B. Blumer +4 more
doaj +1 more source
Personalized medicine : the impact on chemistry [PDF]
, 2010 An effective strategy for personalized medicine requires a major conceptual change in the development and application of therapeutics. In this article, we argue that further advances in this field should be made with reference to another conceptual shift,
Marsh, Andrew +3 more
core +1 more source
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Journal of Pharmacology and Experimental Therapeutics, 2022 RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced ...
G. Traber, A. Yu
semanticscholar +1 more source
, 2020 The CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews, and reports of novel findings of therapeutic relevance to the central nervous system.
Boltze, Johannes +8 more
core +1 more source
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
Journal for ImmunoTherapy of Cancer, 2021 Background NKTR-255 is a novel polyethylene glycol-conjugate of recombinant human interleukin-15 (rhIL-15), which was designed to retain all known receptor binding interactions of the IL-15 molecule. We explored the biologic and pharmacologic differences
Peter Kirk +20 more
doaj +1 more source
A large potentiation effect of serum on the in vitro potency of tulathromycin against Mannheimia haemolytica and Pasteurella multocida [PDF]
, 2016 The antimicrobial properties of tulathromycin were investigated for M.haemolytica and P.multocida. Three invitro indices of antimicrobial activity, minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and time-kill curves ...
Alexander +33 more
core +3 more sources
Digital therapeutics and clinical pharmacology
Translational and Clinical Pharmacology, 2019 Digital therapeutics (DTx) is a new subsection of digital health that is primarily driven by software and will be of great interest to clinical pharmacologists.
J. Chung
semanticscholar +1 more source
Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies [PDF]
, 2017 Background The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available.
Araya, V. +11 more
core +2 more sources
The small quinolone derived compound HT61 enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro and in vivo. [PDF]
, 2020 HT61 is a small quinolone-derived compound previously demonstrated to exhibit bactericidal activity against gram-positive bacteria including methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). When
Amison, RT +6 more
core +1 more source
Pharmacology and Therapeutics of Bronchodilators Revisited
Pharmacological Reviews, 2019 Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest in understanding how to optimize the use of our existing classes of ...
M. Matera +4 more
semanticscholar +1 more source